Abstract
SARS-CoV-2 infection occurs mainly through the respiratory tract; therefore, intranasal immunization represents a promising strategy for eliciting both systemic and mucosal immunity. In this study, we characterized an E. coli-expressed, non-glycosylated Omicron BA.5 receptor-binding domain (RBD) and evaluated its immunogenicity in mice using subcutaneous (s.c.), intranasal (i.n.), and heterologous s.c. prime–i.n. boost (s.c.-i.n.) immunization regimens. Consistent with our previous finding that s.c. immunization induces systemic anti-RBD IgG responses, three s.c. immunizations induced high systemic anti-RBD IgG responses with detectable IgG subclass responses, but no anti-RBD IgA was detected in bronchoalveolar lavage fluid (BAL). In contrast, three-course intranasal immunization (i.n. ×3) and s.c.-i.n. regimens induced systemic anti-RBD IgG and BAL IgA responses with neutralizing activity against SARS-CoV-2 Omicron BA.5 pseudovirus. Altogether, our data suggest that both intranasal and heterologous immunization with an E. coli-expressed non-glycosylated Omicron RBD induces systemic and mucosal antibody responses. These results support further investigation of this antigen for intranasal and heterologous prime-boost vaccination strategies.